Holen Sie sich die Stockscreener-App
5.7439
6.06%
0.3139
Schlusskurs vom Vortag:
$5.43
Offen:
$5.43
24-Stunden-Volumen:
45,414
Relative Volume:
0.10
Marktkapitalisierung:
$322.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
-2.3735
EPS:
-2.42
Netto-Cashflow:
$-68.47M
1W Leistung:
+1.93%
1M Leistung:
+20.48%
6M Leistung:
-35.80%
1J Leistung:
-35.80%
1-Tages-Spanne:
$5.43
$5.9079
1-Wochen-Bereich:
$5.25
$5.9079
52-Wochen-Spanne:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Firmenname
Astria Therapeutics Inc
Sektor
Branche
Telefon
617-349-1971
Adresse
22 BOSTON WHARF ROAD, BOSTON
Vergleichen Sie ATXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
5.7621 | 322.24M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.98 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.25 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.42 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
548.97 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.41 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | TD Cowen | Buy |
| 2023-03-28 | Eingeleitet | Evercore ISI | Outperform |
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
(ATXS) Trading Report - news.stocktradersdaily.com
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace
Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus
Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00 - Defense World
Astria Therapeutics (ATXS) Receives Reiterated Buy Rating and $1 - GuruFocus
Astria Therapeutics (ATXS) Reports Promising Results for Navenib - GuruFocus
Astria Therapeutics Announces Positive Initial Results from the - GuruFocus
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema - MarketScreener
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - Yahoo Finance
California State Teachers Retirement System Increases Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Two Sigma Investments LP Sells 2,042 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Stockholders Approve Key Amendments - TipRanks
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Cantor Fitzgerald Estimates ATXS FY2026 Earnings - Defense World
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace
(ATXS) Investment Report - news.stocktradersdaily.com
Astria Therapeutics to Present at Upcoming European Academy of A - GuruFocus
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress | ATXS Stock News - GuruFocus
Jane Street Group LLC Has $233,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
BNP Paribas Financial Markets Acquires Shares of 5,572 Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Astria Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS Stock News - GuruFocus
ProShare Advisors LLC Invests $140,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Deutsche Bank AG Buys 13,986 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Citizens JMP maintains $25 target on Astria Therapeutics stock By Investing.com - Investing.com Canada
Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference - Business Wire
Janus Henderson Group PLC Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficien - GuruFocus
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop | ATXS Stock News - GuruFocus
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop - Business Wire
Northern Trust Corp Has $4.10 Million Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics to Present at Upcoming Eastern Allergy Confe - GuruFocus
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference | ATXS Stock News - GuruFocus
New Clinical Data: Astria's Navenibart Cuts Hereditary Angioedema Attack Severity, Reduces Rescue Med Usage - Stock Titan
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - New Castle News
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $30.00 - Defense World
Price T Rowe Associates Inc. MD Buys 2,878 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Cantor Fitzgerald Analysts Lower Earnings Estimates for ATXS - Defense World
Wedbush Lowers Earnings Estimates for Astria Therapeutics - Defense World
Q2 EPS Estimate for Astria Therapeutics Lowered by Analyst - Defense World
Astria Therapeutics’ (ATXS) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
FMR LLC Reduces Holdings in Astria Therapeutics Inc - GuruFocus
(ATXS) Technical Data - news.stocktradersdaily.com
Astria Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Astria Therapeutics Reports Increased Loss Amid Rising R&D Costs - TipRanks
Analyst Reiterates Overweight Rating for ATXS with Stable Price Target | ATXS Stock News - GuruFocus
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation - Yahoo Finance
Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):